Glaucoma implant under the microscope: 5-Year safety watch begins
NCT ID NCT04524416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 116 people with open-angle glaucoma who already have a MINIject implant in their eye. Researchers will track them for up to 5 years to see if any serious device-related problems occur. No new treatment is given—this is a safety check to see how well the implant holds up over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MINIject implant (a tiny device placed in the eye to help drain fluid and lower pressure)
What this could lead to
If successful, this study could confirm that the MINIject implant is safe and effective for long-term use, offering a lasting option to control glaucoma without daily eye drops.
What could go wrong
This is an observational follow-up study, not a new treatment trial. It only monitors safety in people who already have the implant, so it cannot prove the implant works better than other options. There is a small risk of device-related eye problems over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN ANGLE GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center Hospotalier Universitaire Genoble Alpes
Grenoble, 38043, France
-
Clinica Oftalmologica del Caribe
Barranquilla, Colombia
-
Hopital de la Croix-Rousse
Lyon, 69417, France
-
Hospital Clínico San Carlos
Madrid, Spain
-
Klinikum der Universität München
München, 81377, Germany
-
Maxivision Eye Hospital
Hyderabad, Telangana, 500034, India
-
Panama Eye Center
Panama City, Panama
-
Uniklinik Köln
Cologne, North Rhine-Westphalia, 50937, Germany
-
Universitätsklinikum Mainz
Mainz, Rhineland-Palatinate, 55131, Germany